Thomas Muster
24Patents
8h-index
35Co-inventors
75Inventor score
Filing activity: Dec 20, 1994 → Jan 24, 2020
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US6468544B1 | Interferon inducing genetically engineered attenuated viruses | Emerging Cross-Sectional Technologies | 35 | Expired |
| US6669943B1 | Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals | Emerging Cross-Sectional Technologies | 33 | Expired |
| US5866694A | Peptides that induce antibodies which neutralize genetically divergent HIV-1 isolates | Emerging Cross-Sectional Technologies | 28 | Expired |
| US6866853B2 | Interferon inducing genetically engineered attenuated viruses | Emerging Cross-Sectional Technologies | 20 | Expired |
| US7588768B2 | Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals | Emerging Cross-Sectional Technologies | 15 | Expired |
| US6022726A | Genetically engineered attenuated viruses | Chemistry; Metallurgy | 11 | Expired |
| US8057803B2 | Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals | Emerging Cross-Sectional Technologies | 11 | Active |
| US5756674A | Peptides that induce antibodies which neutralize genetically divergent HIV-1 isolates | Emerging Cross-Sectional Technologies | 10 | Expired |
| US5693752A | Peptides that induce antibodies which neutralize genetically divergent HIV-1 isolates | Emerging Cross-Sectional Technologies | 6 | Expired |
| US8765139B2 | Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals | Emerging Cross-Sectional Technologies | 2 | Active |
| US9187732B2 | Replication deficient influenza virus for the expression of heterologous sequences | Chemistry; Metallurgy | 1 | Active |
| US9387240B2 | Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals | Emerging Cross-Sectional Technologies | 1 | Active |
| US7510862B2 | Polynucleotide fragments of an infectious human endogenous retrovirus | Physics | 1 | Expired |
| US8541553B2 | Antibodies specific for the melanoma-associated endogenous retrovirus (MERV) envelope glycoprotein | Chemistry; Metallurgy | 0 | Active |
| US8691238B2 | High growth reassortant influenza A virus | Chemistry; Metallurgy | 0 | Active |
| US8741301B2 | Method for generation of RNA virus | Chemistry; Metallurgy | 0 | Active |
| US9771564B2 | Influenza virus | Chemistry; Metallurgy | 0 | Active |
| US10125374B2 | Influenza virus vector for virotherapy | Chemistry; Metallurgy | 0 | Active |
| US10570376B2 | Method for influenza virus purification | Chemistry; Metallurgy | 0 | Active |
| US7282599B2 | Dithiocarbamate antiviral agents and methods of using same | Human Necessities | 0 | Expired |
| US8778357B2 | Method for generation of RNA virus | Chemistry; Metallurgy | 0 | Active |
| US12350325B2 | Recombinant high growth rate influenza virus comprising mutations in M1, NS2, and PB2 | Chemistry; Metallurgy | 0 | Active |
| US8008460B2 | Polynucleotide fragments of an infectious human endogenous retrovirus | Physics | 0 | Active |
| US10480013B2 | Influenza virus vector for virotherapy | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.